Premium
Progress in interleukin‐2 therapy for rheumatic immune diseases by regulating the immune balance of T cells
Author(s) -
Shao Qin,
Gao Hongyan
Publication year - 2019
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12822
Subject(s) - immune system , immunology , effector , pathogenesis , t cell , immunity , interleukin 23 , medicine , biology , interleukin 17
Breaking the balance between effector T cells, including Th17 (T helper cell 17) cells, and regulatory T cells (Tregs) is a key link in the pathogenesis of rheumatic immune diseases, which lead to a new concept of regulating immune balance in the treatment of rheumatic immune diseases. Interleukin (IL)‐2 can effectively regulate the differentiation, development and functional activity of regulatory T cells, thus restoring the immune balance between regulatory T cells and effector T cells. Therefore, low‐dose IL‐2 has been used in the treatment of rheumatic immune diseases, and it has become a promising new choice to achieve therapeutic purpose by regulating the immune balance of T cell. Here, we discuss the role of T cells immune imbalance in the pathogenesis of rheumatic immune diseases and the mechanism of IL‐2 in the treatment of rheumatic immune diseases by regulating T cells immune balance and summarize the relevant clinical trials.